Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (NASDAQ: AKTX), società biotecnologica nel settore oncologico specializzata in conjugati di anticorpi con farmaco (ADC) a payload, parteciperà al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025 a New York.
Il CEO Abizer Gaslightwala terrà una presentazione e incontrerà singolarmente gli investitori registrati. La presentazione sarà disponibile tramite webcast video a partire dal 5 settembre 2025 alle 07:00 ET per i partecipanti registrati e resterà consultabile sul sito web dell'azienda per 90 giorni.
Akari Therapeutics (NASDAQ: AKTX), una compañía biotecnológica oncológica centrada en conjugados anticuerpo-fármaco (ADC) con payload, participará en la H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025 en Nueva York.
El CEO Abizer Gaslightwala ofrecerá una presentación y mantendrá reuniones individuales con inversores registrados. La presentación estará disponible por webcast de video desde el 5 de septiembre de 2025 a las 07:00 ET para los asistentes registrados y permanecerá accesible en la web de la compañía durante 90 días.
Akari Therapeutics (NASDAQ: AKTX)는 페이로드 항체-약물 접합체(ADC)를 중심으로 한 종양학 바이오테크 기업으로, 2025년 9월 8일부터 10일까지 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference에 참가합니다.
CEO 아비저 가슬라이트왈라(Abizer Gaslightwala)가 발표를 진행하고 등록된 투자자들과 일대일 미팅을 가질 예정입니다. 발표는 2025년 9월 5일 오전 7:00(동부시간)부터 비디오 웹캐스트로 등록 참가자에게 제공되며, 회사 웹사이트에서 90일간 시청할 수 있습니다.
Akari Therapeutics (NASDAQ: AKTX), une société biotechnologique oncologique spécialisée dans les conjugués anticorps-médicament (ADC) à payload, participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025 à New York.
Le PDG Abizer Gaslightwala présentera et tiendra des réunions individuelles avec les investisseurs inscrits. La présentation sera disponible en webdiffusion vidéo à partir du 5 septembre 2025 à 07:00 ET pour les participants inscrits et restera accessible sur le site de la société pendant 90 jours.
Akari Therapeutics (NASDAQ: AKTX), ein onkologisches Biotechnologieunternehmen, das sich auf Fracht-Antikörper-Wirkstoff-Konjugate (ADCs) spezialisiert hat, wird an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 in New York teilnehmen.
CEO Abizer Gaslightwala wird eine Präsentation halten und Einzelgespräche mit registrierten Investoren führen. Die Präsentation ist für registrierte Teilnehmer ab dem 5. September 2025 um 07:00 Uhr ET als Videowebcast verfügbar und bleibt für 90 Tage auf der Unternehmenswebsite abrufbar.
- None.
- None.
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Friday, September 5, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Presentations page in the Investors section of the Company’s website (akaritx.com). The webcast replay will be archived for 90 days following the event.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When is Akari Therapeutics (AKTX) presenting at the H.C. Wainwright Conference 2025?
How can investors watch Akari Therapeutics' H.C. Wainwright conference presentation?
Who will represent Akari Therapeutics at the H.C. Wainwright conference?
How long will Akari Therapeutics' conference presentation be available for viewing?
